Sodium voltage-gated channel alpha subunit 9
Sodium Voltage-Gated Channel Alpha Subunit 9[edit]

The sodium voltage-gated channel alpha subunit 9, also known as Nav1.7, is a protein that in humans is encoded by the SCN9A gene. This protein is a part of the voltage-gated sodium channel family, which is crucial for the initiation and propagation of action potentials in neurons.
Structure[edit]
Nav1.7 is a transmembrane protein that forms a pore through which sodium ions can pass. It is composed of four homologous domains, each containing six transmembrane segments. The fourth segment in each domain acts as the voltage sensor, while the loop between the fifth and sixth segments forms the ion-conducting pore.
Function[edit]
Nav1.7 channels are primarily expressed in the peripheral nervous system, particularly in nociceptors, which are sensory neurons responsible for the detection of painful stimuli. These channels play a critical role in the generation and conduction of action potentials in response to noxious stimuli, thus contributing to the sensation of pain.
Clinical Significance[edit]
Mutations in the SCN9A gene can lead to a variety of pain disorders. Gain-of-function mutations are associated with conditions such as primary erythromelalgia and paroxysmal extreme pain disorder, where patients experience episodes of severe pain. Conversely, loss-of-function mutations can result in congenital insensitivity to pain, a condition where individuals cannot feel pain, leading to an increased risk of injury.
Pharmacology[edit]
Nav1.7 is a target for the development of new analgesic drugs. Selective blockers of this channel are being investigated as potential treatments for chronic pain conditions, as they may provide pain relief without the side effects associated with traditional pain medications like opioids.
Research[edit]
Ongoing research is focused on understanding the precise mechanisms by which Nav1.7 contributes to pain signaling and how it can be modulated to treat pain. Structural studies, such as those using cryo-electron microscopy, have provided detailed insights into the channel's architecture, aiding in the design of specific inhibitors.
Related Pages[edit]
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian